| 英文名称 | CAS号 | 中文名 | 中文别名 | 分子式 | 分子量 | EINECS号 |
|---|---|---|---|---|---|---|
|
Mubritinib
|
366017-09-6 |
木利替尼
|
莫布利替尼;莫立替尼,木利替尼;莫利替尼;1-(4-(4-((2-((1E)-2-(4-(三氟甲基)苯基)乙烯基)-4-恶唑基)甲氧基)苯基)丁基)-1H-1,2,3-三氮唑;TAK165;TAK-165;CS-522;莫立替尼、TAK 166;木利替尼;莫立替尼
|
C25H23F3N4O2 |
468.47 | |
|
CP-724714
|
537705-08-1 |
2-甲氧基-N-[3-[4-[[3-甲基-4-[(6-甲基-3-吡啶基)氧基]苯基]氨基]-6-喹唑啉基]-2-丙烯-1-基]乙酰胺
|
CS-521;CS-2401;2-甲氧基-N-[3-[4-[[3-甲基-4-[(6-甲基-3-吡啶基)氧基]苯基]氨基]-6-喹唑啉基]-2-丙烯-1-基]乙酰胺
|
C27H27N5O3 |
469.53498 | |
|
Fasudil hydrochloride
|
105628-07-7 |
盐酸法舒地尔
|
六氢-1-(5-异喹啉磺酰基)-1H-1,4-二氮杂卓盐酸盐;盐酸法舒地尔;盐酸法舒地尔/六氢-1-(5-异喹啉磺酰基)-1H-1,4-二氮杂卓盐酸盐;酸法舒地尔;CS-1572;六氢-1-(5-磺酰基异喹啉)-1(H)-1,4-二氮杂卓盐酸盐
|
C14H18ClN3O2S |
327.83 | 805-833-0 |
|
lonafarnib
|
193275-84-2 |
4-[2-[4-[(11R)-3,1-二溴-8-氯-6,11-二氢-5H-苯并[5,6]环庚并[1,2-B]吡啶-11-基]-1-哌啶基]-2-氧代乙基]-1-哌啶甲酰胺
|
SARASAR;SCH 66336;SCH66336;SCH-66336;4-[2-[4-[(11R)-3,10-二溴-8-氯-6,11-二氢-5H-苯并[5,6]环庚并[1,2-B]吡啶-11-基]-1-哌啶基]-2-氧代乙基]-2-哌啶甲酰胺;洛那法尼;洛那法尼(抗癌类抗白血病药);氯那法尼
|
C27H31Br2ClN4O2 |
638.82 | |
|
TAK-700 (Orteronel)
|
566939-85-3 |
6-[(7S)-7-羟基-6,7-二氢-5H-吡咯并[1,2-C]咪唑-7-基]-N-甲基-2-萘甲酰胺
|
CYP17A1 Inhibitor II, TAK-700 - CAS 566939-85-3 - Calbiochem;6-[(7S)-7-Hydroxy-6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-7-yl]-N-methyl-2-naphthalenecarboxamide;Orteronel;TAK-700 (S-form);TAK-700 (Orteronel);Orteronel, >=98%;(S)-Orteronel
|
C18H17N3O2 |
307.34648 | |
|
TH-302
|
918633-87-1 |
N,N'-双(2-溴乙基)二氨基膦酸 (1-甲基-2-硝基-1H-咪唑-5-基)甲酯
|
(1-Methyl-2-nitro-1H-imidazol-5-yl)methyl N,N'-bis(2-bromoethyl)phosphorodiamidate;N,N'-Bis(2-bromoethyl)phosphorodiamidic acid (1-methyl-2-nitro-1H-imidazol-5-yl)methyl ester;TH 302;EvofosfaMide;TH-302, >=98%;TH-302 (Evofosfamide);(1-methyl-2-nitro-1H-imidazol-5-yl)methylN,N'-bis(2-bromoethyl)diamidophosphate;EOS-61724
|
C9H16Br2N5O4P |
449.036201 | |
|
pimobendan
|
74150-27-9 |
匹莫苯丹
|
匹莫苯旦;匹莫苯丹 1G;匹莫苯,匹莫苯丹;VETMEDIN;ACARDI;PIMOBENDANE;心血管系统用药-匹莫苯丹;匹莫苯;匹莫苯丹;6-[2-(4-甲氧基苯基)-1H-苯并咪唑-5-基]-5-甲基-4,5-二氢-3(2H)-哒嗪酮;4,5-二氢-5-甲基-6-[2-(4-甲氧基苯基)-1H-苯并咪唑-5-基]-3(3H)一哒嗪酮
|
C19H18N4O2 |
334.37 | 640-420-7 |
|
E 2012
|
870843-42-8 |
(E)-1-[(1S)-1-(4-氟苯基)乙基]-3-[3-甲氧基-4-(4-甲基-1H-咪唑-1-YL)亚苄基]哌啶-2-酮
|
(E)-1-[(1S)-1-(4-氟苯基)乙基]-3-[3-甲氧基-4-(4-甲基-1H-咪唑-1-基)亚苄基]哌啶-2-酮;(E)-1-[(1S)-1-(4-氟苯基)乙基]-3-[3-甲氧基-4-(4-甲基-1H-咪唑-1-YL)亚苄基]哌啶-2-酮;(E)-1-[(1S)-1-(4-氟苯基)乙基]-3-[3-甲氧基-4-(4-甲基-1H-咪唑-1-基)亚苄基]哌啶-2-酮;E2012;E 2012;E-2012;E-2012;E2012
|
C25H26FN3O2 |
419.49 | |
|
LY-411575
|
209984-57-6 |
(AS)-N-[(1S)-2-[[(7S)-6,7-二氢-5-甲基-6-氧代-5H-二苯并[B,D]氮杂卓-7-基]氨基]-1-甲基-2-氧代乙基]-3,5-二氟-ALPHA-羟基苯乙酰胺
|
(AS)-N-[(1S)-2-[[(7S)-6,7-二氢-5-甲基-6-氧代-5H-二苯并[B,D]氮杂卓-7-基]氨基]-1-甲基-2-氧代乙基]-3,5-二氟-ALPHA-羟基苯乙酰胺;(AS)-N-[(1S)-2-[[(7S)-6,5-二氟-ALPHA-羟基苯乙酰胺 500MG;LY411575,一种Γ-SECRETASE抑制剂
|
C26H23F2N3O4 |
479.481 | |
|
LY2603618 (IC-83)
|
911222-45-2 |
N-[5-溴-4-甲基-2-[(2S)-2-吗啉甲氧基]苯基]-N'-(5-甲基-2-吡嗪基)脲
|
RABUSERTIB;IC-83;IC-83;LY 2603618;LY-2603618;CS-508;N-[5-溴-4-甲基-2-[(2S)-2-吗啉甲氧基]苯基]-N'-(5-甲基-2-吡嗪基)脲
|
C18H22BrN5O3 |
436.32 | |
|
ABT-751
|
141430-65-1 |
N-[2-[(4-羟基苯基)氨基]-3-吡啶基]-4-甲氧基苯磺酰胺
|
ABT751;ABT 751;E7010;E-7010;E 7010;CS-1806;CS-505;N-[2-[(4-羟基苯基)氨基]吡啶-3-基]-4-甲氧基苯磺酰胺;ABT-751 (E7010);ABT751;ABT 751;N-[2-[(4-羟基苯基)氨基]-3-吡啶基]-4-甲氧基苯磺酰胺
|
C18H17N3O4S |
371.41028 | 256-495-9 |
|
Geldanamycin
|
30562-34-6 |
格尔德霉素
|
格尔德霉素杂质;格尔德霉素,≥98%;NSC-122750; NSC 122750; NSC122750;格尔德美素;格尔德霉素;格尔德美素;格尔德霉素(抗癌类)
|
C29H40N2O9 |
560.64 | 999-999-2 |
|
(S)-2-(2-((S)-2-acetamido-4-methylpentanamido)acetamido)-N-(4-methyl-2-oxo-2H-chromen-7-yl)-6-(2,2,2-trifluoroacetamido)hexanamide
|
1026295-98-6 |
(S)-2-(2-((S)-2-ACETAMIDO-4-METHYLPENTANAMIDO)ACETAMIDO)-N-(4-METHYL-2-OXO-2H-CHROMEN-7-YL)-6-(2,2,2-TRIFLUOROACETAMIDO)HEXANAMIDE
|
N-乙酰基-L-亮氨酰甘氨酰-N-(4-甲基-2-氧代-2H-1-苯并吡喃-7-基)-N6-(2,2,2-三氟乙酰基)-L-赖氨酰胺
|
C28H36F3N5O7 |
612 | |
|
Azelnidipine
|
123524-52-7 |
阿折地平
|
阿折地平;阿折地坪;CS-500;阿折地平(研发中);AZELNIDIPINE (阿折地平;CALBLOCK)是二氢吡啶衍生物,为L型钙离子通道阻断剂,可抗高血压。
|
C33H34N4O6 |
582.65 | 634-143-0 |
|
PD 169316
|
152121-53-4 |
4-[4-(4-氟苯基)-2-(4-硝基苯基)-1H-咪唑-5-基]吡啶
|
PD 169316>97%;CS-497;4-[4-(4-氟苯基)-2-(4-硝基苯基)-1H-咪唑-5-基]吡啶
|
C20H13FN4O2 |
360.347 | 200-256-5 |
|
Nebivolol Hydrochloride
|
152520-56-4 |
盐酸奈必洛尔
|
盐酸萘必洛尔;奈必洛尔盐酸盐,一种选择性Β1拮抗剂;奈必洛尔盐酸盐;奈比洛尔盐酸盐;双[2-(6-氟苯并二氢吡喃-2-基)-3-羟基乙基]胺盐酸盐;盐酸奈必洛尔;盐酸奈必诺尔
|
C22H25F2NO4.HCL |
441.9 | |
|
FABP4 Inhibitor
|
300657-03-8 |
[2'-(5-ETHYL-3,4-DIPHENYL-PYRAZOL-1-YL)-BIPHENYL-3-YLOXY]-ACETIC ACID
|
BMS 309403;BMS309403;2-[[2'-(5-乙基-3,4-二苯基-1H-吡唑-1-基)[1,1'-联苯]-3-基]氧基]乙酸;BMS309403;2-(5-乙基-3,4-二苯基-吡唑-1-基)-联苯-3-基氧基]乙酸
|
C31H26N2O3 |
474.557 | |
|
Pnumocandin-BO
|
135575-42-7 |
纽莫康定 B
|
纽莫康定 B0;纽莫康定(肺囊康定)B0;纽莫康定 B0;纽莫康定;纽莫康定B0((肺囊康定);卡泊芬净中间体;卡泊芬净中间体(纽莫康定 B0)
|
C50H80N8O17 |
1065.21 | 629-746-0 |
|
erlotinib hydrochloride
|
183319-69-9 |
盐酸埃罗替尼
|
盐酸厄洛替尼;盐酸厄罗替尼;盐酸矣罗替尼;埃罗替尼工作对照品;埃罗替尼,厄洛替尼;盐酸埃罗替尼(替尼类);N-(3-乙炔苯基)-6,7-双(2-甲氧乙氧基)-5-喹啉胺盐酸盐;厄洛替尼API;盐酸埃罗替尼(标准品);盐酸厄洛替尼
|
C22H23N3O4·HCl |
429.9 | |
|
(S)-duloxetine hydrochloride
|
136434-34-9 |
盐酸度洛西汀
|
CS-488;盐酸度洛西汀 1.0 MG;ML;盐酸度洛西汀杂质;度洛西林盐酸盐;(+)-(S)-N-METHYL-3-(1-NAPHTHYLOXY)-3-(2-THIENYL)PROPANAMINE HYDROCHLORIDE;右旋度;(S)-N-甲基-3-(萘-1-氧基)-3-(噻吩-2-基)丙-1-胺盐酸盐;盐酸度洛西汀,≥98.0%
|
C18H19NOS·HCl;C18H20ClNOS |
333.88 | 603-962-5 |
药智官方微信
药智官方微博
